Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2026—The Food and Drug Administration has granted breakthrough device designation to the NG-Test Candida auris and NG-Test Acineto-5 assays, which are developed and manufactured in France by NG Biotech and distributed exclusively in the United States by Hardy Diagnostics.
April 2026—The FDA has granted breakthrough device designation to MeMed’s BV Flex, a blood test designed to distinguish between bacterial and viral infections based on the body’s immune response.
April 2026—Devyser has entered into a strategic agreement with Illumina in which Devyser will offer selected Illumina sequencing instruments with Devyser’s reagent solutions.
April 2026—Invivoscribe has added the LeukoStrat KMT2A + MRD assay and software to its oncology portfolio.
April 2026—Fujirebio and Sysmex have agreed on a sales collaboration in which Sysmex will exclusively sell Fujirebio’s fully automated Lumipulse immunoassay systems and reagents for dementia testing.
April 2026—Biocartis’ Idylla CDx MSI test has received class C companion diagnostic certification under the European Union IVDR.
April 2026—The Food and Drug Administration has granted 510(k) clearance for Randox USA’s clinical drug testing panel.
April 2026—A new report from KLAS Research awarded Proscia the highest overall performance score (95.2) in the U.S. market, based on customer feedback.
April 2026—Leica Biosystems launched in the U.S. the Aperio GT Elite scanner and Aperio iQC software.
April 2026—Thermo Fisher Scientific launched the TacroType pharmacogenetic test, a laboratory-developed test designed to help inform clinicians on dosing tacrolimus, an immunosuppressive drug for transplant recipients.
